2026 Q1 -tulosraportti
26 päivää sitten
‧29 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 540 | - | - | ||
| 3 137 | - | - | ||
| 149 | - | - | ||
| 108 | - | - | ||
| 43 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 144 183 | 144 183 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 144 183 | 144 183 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·9 t sitten
·1 päivä sitten · MuokattuWithin a couple of days, the 50-day simple moving average (SMA 50) will cross up through the SMA 200. This is called a Golden Cross, and is a strong signal that the stock has reversed a negative/flat trend and is now in a strong upward trend. There are people who swear by TA, so it will be interesting to follow the price over the next couple of days.·12 t sittenmuldyr, even though I am not a TA myself, I often look at what the TAs say. I think one should, as many trade based on TA and consequently can affect the price. In the case of BP, however, I don't attach much importance to TA. The reason is the low turnover. It is indeed low, so even a private investor, so to speak, can order the TA formation he desires, which I think undermines TA a bit here. But we'll see. The delay and significant extra cost BP just received as a gift from the FDA is a setback and a slap that can be felt in little fragile BP. If TAs think it should go up on that, be my quest.
·10.6.From DNB Carnegie's NEWS FLASH NOTE on June 9, 2026 * Focuses on KDIGO guidelines as the next trigger. They have changed the timing from 2H to Q3 2026 **Fair value interval of DKK0.5–3.0 per share over 12 months is reiterated. From DNB Carnegie's RESULTS UPDATE NOTE on May 21, 2026 ***Acquisition a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. Based on our 2032 estimates, we calculate that this would imply an equity value of ~DKK4.7–5.6/share (discounted with a 16.5% WACC). Let's say the company is acquired in 3-5 years at 5 DKK/share (mid-point of DNB Carnegie's estimate). I.e. 4x current price. Worth waiting for? Important assumptions are falling into place with the positive announcements from the FDA this year and guidelines from KDIGO later this year.- ·10.6.Watch or rewatch https://www.youtube.com/watch?v=tmGjhrI-SLY·11.6.I can well understand that it sounds completely crazy Mathias, what I wrote yesterday, regarding RUO If it's completely off the mark. 1. where do the huge revenues come from, which management says are coming, KW said verbatim, that there will be, ramp up, just for the sake of good order, I looked it up, and it literally means. rapidly increases its activity, production or sales. 2. If the following is completely crazy Matias and it's pure fantasy on my part, how do we then explain, this wild revenue that KW said would come, when BP will only sell the NGAL test to children's hospitals, and adult hospitals, are excluded? 3. BP has also not downgraded the number of hospitals 60+ They " only" need 900 patients and they have that, at the 4 university hospitals, which they got in Q1. So how will they be able to achieve 60+ hospitals in 2026, when they don't need more adult hospitals, to satisfy FDA's requirements, for 900 patients? I'd be happy to provide an answer.. There can only be 60+ hospitals, and CB and KW can only ramp up, if they go under FDA's radar, and use the method below. Because so many tests. will not be needed at children's hospitals throughout the USA, for BP to meet their guidance? If you have other suggestions, how they can ramp up, now that FDA has excluded, that Bioporto may sell to adult hospitals, I would be happy to read it. If you don't have an alternative suggestion, but only come with sour remarks, then you don't need to, spend energy on, writing anything at all.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
26 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sitten
- ·1 päivä sitten · MuokattuWithin a couple of days, the 50-day simple moving average (SMA 50) will cross up through the SMA 200. This is called a Golden Cross, and is a strong signal that the stock has reversed a negative/flat trend and is now in a strong upward trend. There are people who swear by TA, so it will be interesting to follow the price over the next couple of days.·12 t sittenmuldyr, even though I am not a TA myself, I often look at what the TAs say. I think one should, as many trade based on TA and consequently can affect the price. In the case of BP, however, I don't attach much importance to TA. The reason is the low turnover. It is indeed low, so even a private investor, so to speak, can order the TA formation he desires, which I think undermines TA a bit here. But we'll see. The delay and significant extra cost BP just received as a gift from the FDA is a setback and a slap that can be felt in little fragile BP. If TAs think it should go up on that, be my quest.
- ·10.6.From DNB Carnegie's NEWS FLASH NOTE on June 9, 2026 * Focuses on KDIGO guidelines as the next trigger. They have changed the timing from 2H to Q3 2026 **Fair value interval of DKK0.5–3.0 per share over 12 months is reiterated. From DNB Carnegie's RESULTS UPDATE NOTE on May 21, 2026 ***Acquisition a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. Based on our 2032 estimates, we calculate that this would imply an equity value of ~DKK4.7–5.6/share (discounted with a 16.5% WACC). Let's say the company is acquired in 3-5 years at 5 DKK/share (mid-point of DNB Carnegie's estimate). I.e. 4x current price. Worth waiting for? Important assumptions are falling into place with the positive announcements from the FDA this year and guidelines from KDIGO later this year.
- ·10.6.Watch or rewatch https://www.youtube.com/watch?v=tmGjhrI-SLY·11.6.I can well understand that it sounds completely crazy Mathias, what I wrote yesterday, regarding RUO If it's completely off the mark. 1. where do the huge revenues come from, which management says are coming, KW said verbatim, that there will be, ramp up, just for the sake of good order, I looked it up, and it literally means. rapidly increases its activity, production or sales. 2. If the following is completely crazy Matias and it's pure fantasy on my part, how do we then explain, this wild revenue that KW said would come, when BP will only sell the NGAL test to children's hospitals, and adult hospitals, are excluded? 3. BP has also not downgraded the number of hospitals 60+ They " only" need 900 patients and they have that, at the 4 university hospitals, which they got in Q1. So how will they be able to achieve 60+ hospitals in 2026, when they don't need more adult hospitals, to satisfy FDA's requirements, for 900 patients? I'd be happy to provide an answer.. There can only be 60+ hospitals, and CB and KW can only ramp up, if they go under FDA's radar, and use the method below. Because so many tests. will not be needed at children's hospitals throughout the USA, for BP to meet their guidance? If you have other suggestions, how they can ramp up, now that FDA has excluded, that Bioporto may sell to adult hospitals, I would be happy to read it. If you don't have an alternative suggestion, but only come with sour remarks, then you don't need to, spend energy on, writing anything at all.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 540 | - | - | ||
| 3 137 | - | - | ||
| 149 | - | - | ||
| 108 | - | - | ||
| 43 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 144 183 | 144 183 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 144 183 | 144 183 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
26 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sitten
- ·1 päivä sitten · MuokattuWithin a couple of days, the 50-day simple moving average (SMA 50) will cross up through the SMA 200. This is called a Golden Cross, and is a strong signal that the stock has reversed a negative/flat trend and is now in a strong upward trend. There are people who swear by TA, so it will be interesting to follow the price over the next couple of days.·12 t sittenmuldyr, even though I am not a TA myself, I often look at what the TAs say. I think one should, as many trade based on TA and consequently can affect the price. In the case of BP, however, I don't attach much importance to TA. The reason is the low turnover. It is indeed low, so even a private investor, so to speak, can order the TA formation he desires, which I think undermines TA a bit here. But we'll see. The delay and significant extra cost BP just received as a gift from the FDA is a setback and a slap that can be felt in little fragile BP. If TAs think it should go up on that, be my quest.
- ·10.6.From DNB Carnegie's NEWS FLASH NOTE on June 9, 2026 * Focuses on KDIGO guidelines as the next trigger. They have changed the timing from 2H to Q3 2026 **Fair value interval of DKK0.5–3.0 per share over 12 months is reiterated. From DNB Carnegie's RESULTS UPDATE NOTE on May 21, 2026 ***Acquisition a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. Based on our 2032 estimates, we calculate that this would imply an equity value of ~DKK4.7–5.6/share (discounted with a 16.5% WACC). Let's say the company is acquired in 3-5 years at 5 DKK/share (mid-point of DNB Carnegie's estimate). I.e. 4x current price. Worth waiting for? Important assumptions are falling into place with the positive announcements from the FDA this year and guidelines from KDIGO later this year.
- ·10.6.Watch or rewatch https://www.youtube.com/watch?v=tmGjhrI-SLY·11.6.I can well understand that it sounds completely crazy Mathias, what I wrote yesterday, regarding RUO If it's completely off the mark. 1. where do the huge revenues come from, which management says are coming, KW said verbatim, that there will be, ramp up, just for the sake of good order, I looked it up, and it literally means. rapidly increases its activity, production or sales. 2. If the following is completely crazy Matias and it's pure fantasy on my part, how do we then explain, this wild revenue that KW said would come, when BP will only sell the NGAL test to children's hospitals, and adult hospitals, are excluded? 3. BP has also not downgraded the number of hospitals 60+ They " only" need 900 patients and they have that, at the 4 university hospitals, which they got in Q1. So how will they be able to achieve 60+ hospitals in 2026, when they don't need more adult hospitals, to satisfy FDA's requirements, for 900 patients? I'd be happy to provide an answer.. There can only be 60+ hospitals, and CB and KW can only ramp up, if they go under FDA's radar, and use the method below. Because so many tests. will not be needed at children's hospitals throughout the USA, for BP to meet their guidance? If you have other suggestions, how they can ramp up, now that FDA has excluded, that Bioporto may sell to adult hospitals, I would be happy to read it. If you don't have an alternative suggestion, but only come with sour remarks, then you don't need to, spend energy on, writing anything at all.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 540 | - | - | ||
| 3 137 | - | - | ||
| 149 | - | - | ||
| 108 | - | - | ||
| 43 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 144 183 | 144 183 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 144 183 | 144 183 | 0 | 0 |